What is SanegeneBio?
Founded in 2021, SanegeneBio operates globally with R&D centers in Boston, Shanghai, and Suzhou. The company is dedicated to leveraging RNAi technology to create blockbuster medicines across diverse therapeutic areas, aiming to enhance patient quality and longevity. SanegeneBio's pipeline includes experimental medicines targeting autoimmune nephropathies, obesity, and cardiometabolic indications, with four such therapies already in clinical trials. Their proprietary LEAD tissue-selective RNAi delivery technology is central to their strategy of developing potential best-in-class and first-in-class therapeutics.
How much funding has SanegeneBio raised?
SanegeneBio has raised a total of $110M across 1 funding round:
Series B
$110M
Series B (2025): $110M with participation from Lilly, Hillhouse, Legend Capital, and China Biopharma
Key Investors in SanegeneBio
Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines, with a focus on diabetes, oncology, immunology, and neuroscience.
Hillhouse
Hillhouse is a full life-cycle private equity firm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors.
Legend Capital
Legend Capital is a private equity fund manager focused on innovation and growth enterprises with operations in or related to China, managing significant capital across USD and RMB funds.
What's next for SanegeneBio?
The recent major strategic investment signals SanegeneBio's transition into a scaling phase, likely to accelerate the clinical development and potential commercialization of its promising pipeline. This capital infusion is expected to bolster its R&D efforts, expand its operational footprint, and solidify its position in the competitive RNAi therapeutics market. The company's focus on addressing significant unmet medical needs in areas like autoimmune diseases and metabolic disorders positions it for substantial growth and impact.
See full SanegeneBio company page
